DCE-MRI using small-molecular and albumin-binding contrast agents in experimental carcinomas with different stromal content

European Journal of Radiology

Volumn 78, Issue 1, 2011, Pages 52-59

  Farace, Paolo ^a   Merigo, Flavia ^a   Fiorini, Silvia ^a   Nicolato, Elena ^a   Tambalo, Stefano ^a   Daducci, Alessandro ^a   Degrassi, Anna ^b   Sbarbati, Andrea ^a   Rubello, Domenico ^c   Marzola, Pasquina ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b NERVIANO MEDICAL SCIENCES   (Italy)

^c S MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

Carcinoma; DCE MRI; MS 325; Stroma

Indexed keywords

CD31 ANTIGEN; GADOFOSVESET; GADOLINIUM PENTETATE; VASCULOTROPIN;

ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER SIZE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; EX VIVO STUDY; EXPERIMENTAL NEOPLASM; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUANTITATIVE ANALYSIS; STROMA;

ANIMALS; CELL LINE, TUMOR; CONTRAST MEDIA; GADOLINIUM; GADOLINIUM DTPA; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMMUNOENZYME TECHNIQUES; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; ORGANOMETALLIC COMPOUNDS; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS;

EID: 79954875973     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2009.04.043     Document Type: Article

References (33)

1. N.A. Bhowmick, E.G. Neilson, and H.L. Moses Stromal fibroblasts in cancer initiation and progression Nature 432 2004 332 337 (Pubitemid 39551661)
2. M.I. Koukourakis, A. Giatromanolaki, and A.L. Harris Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma Cancer Res 66 2006 632 637 (Pubitemid 43165922)
3. A.E. Karnoub, A.B. Dash, and A.P. Vo Mesenchymal stem cells within tumour stroma promote breast cancer metastasis Nature 449 2007 557 563 (Pubitemid 47525152)
4. S.E. Moody, D. Perez, and T.C. Pan The transcriptional repressor Snail promotes mammary tumor recurrence Cancer Cell 8 2005 197 209 (Pubitemid 41317591)
5. O. De Wever, and M. Mareel Role of tissue stroma in cancer cell invasion J Pathol 200 2003 429 447 (Pubitemid 36818244)
6. A. Orimo, P.B. Gupta, and D.C. Sgroi Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion Cell 121 2005 335 348 (Pubitemid 40692295)
7. C.M. Zechmann, E.C. Woenne, and G. Brix Impact of stroma on the growth, microcirculation, and metabolism of experimental prostate tumors Neoplasia 9 2007 57 67 (Pubitemid 46203934)
8. K.L. Knutson, B. Almand, and Y. Dang Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice Cancer Res 64 2004 1146 1151 (Pubitemid 38176922)
9. K.L. Knutson, H. Lu, and B. Stone Immunoediting of cancers may lead to epithelial to mesenchymal transition J Immunol 177 2006 1526 1533 (Pubitemid 44092486)
10. R.F. Hwang, T. Moore, and T. Arumugam Cancer-associated stromal fibroblasts promote pancreatic tumor progression Cancer Res 68 2008 918 926 (Pubitemid 351206771)
11. M. Korc Pancreatic cancer-associated stroma production Am J Surg 194 2007 S84 S86
12. V. Hofmeister, D. Schrama, and J.C. Becker Anti-cancer therapies targeting the tumor stroma Cancer Immunol Immunother 57 2008 1 17 (Pubitemid 350043655)
13. G. Lucignani PET-MRI synergy in molecular, functional and anatomical cancer imaging Eur J Nucl Med Mol Imaging 35 2008 1550 1553
14. P. Farace, D. D'Ambrosio, and F. Merigo Cancer-associated stroma affects FDG uptake in experimental carcinomas - implications for FDG-PET delineation of radiotherapy target Eur J Nucl Med Mol Imaging December 2008
15. M. Gali, P. Farace, and C. Nanni Epithelial and mesenchymal tumor compartments exhibit in vivo complementary patterns of vascular perfusion and glucose metabolism Neoplasia 9 2007 900 908 (Pubitemid 350086435)
16. P. Farace, M. Gali, and C. Nanni Contouring carcinomas by FDG-PET: is the role of tumor biology underestimated? In regard to MacManus et al. (Int J Radiat Oncol Biol Phys 2008;71:2-4). Int J Radiat Oncol Biol Phys 72 2008 303 304
17. S.M. Noworolski, R.G. Henry, and D.B. Vigneron Dynamic contrast-enhanced MRI in normal and abnormal prostate tissues as defined by biopsy, MRI, and 3D MRSI Magn Reson Med 53 2005 249 255 (Pubitemid 40171038)
18. J. Ren, Y. Huan, and H. Wang Dynamic contrast-enhanced MRI of benign prostatic hyperplasia and prostatic carcinoma: correlation with angiogenesis Clin Radiol 63 2008 153 159
19. G. Jia, J.T. Heverhagen, and H. Henry Pharmacokinetic parameters as a potential predictor of response to pharmacotherapy in benign prostatic hyperplasia: a preclinical trial using dynamic contrast-enhanced MRI Magn Reson Imaging 24 2006 721 725 (Pubitemid 43974887)
20. J.T. Heverhagen, H. von Tengg-Kobligk, and K.T. Baudendistel Benign prostate hyperplasia: evaluation of treatment response with DCE MRI MAGMA 17 2004 5 11 (Pubitemid 39390398)
21. G.M. Tse, B. Chaiwun, and K.T. Wong Magnetic resonance imaging of breast lesions - a pathologic correlation Breast Cancer Res Treat 103 2007 1 10 (Pubitemid 46653267)
22. L.D. Buadu, J. Murakami, and S. Murayama Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis Radiology 200 1996 639 649 (Pubitemid 26282258)
23. K. Shamsi, E.K. Yucel, and P. Chamberlin A summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: phase II and phase III clinical trials data. Invest Radiol 41 2006 822 830 (Pubitemid 44566363)
24. P. Marzola, S. Ramponi, and E. Nicolato Effect of tamoxifen in an experimental model of breast tumor studied by dynamic contrast-enhanced magnetic resonance imaging and different contrast agents Invest Radiol 40 2005 421 429 (Pubitemid 40863785)
25. S.A. Mullamitha, N.C. Ton, and G.J. Parker Phase I evaluation of a fully human anti-alpha-v integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors Clin Cancer Res 13 2007 2128 2135 (Pubitemid 46649882)
26. G. Antoch, L.S. Freudenberg, and T. Beyer To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT J Nucl Med 45 Suppl. 2004 S56 S65
27. A.C. Pfannenberg, P. Aschoff, and K. Brechtel Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer Eur J Nucl Med Mol Imaging 34 2007 36 44 (Pubitemid 44885552)
28. D.E. Soto, M.L. Kessler, and M. Piert Correlation between pretreatment FDG-PET biological target volume and anatomical location of failure after radiation therapy for head and neck cancers Radiother Oncol 89 2008 13 18
29. I. Madani, W. Duthoy, and C. Derie Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer Int J Radiat Oncol Biol Phys 68 2007 126 135 (Pubitemid 46589860)
30. G. Delso, and S. Ziegler PET/MRI system design Eur J Nucl Med Mol Imaging December 2008
31. G. Antoch, and A. Bockisch Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur J Nucl Med Mol Imaging December 2008
32. M.S. Judenhofer, H.F. Wehrl, and D.F. Newport Simultaneous PET-MRI: a new approach for functional and morphological imaging Nat Med 14 2008 459 465 (Pubitemid 351499385)
33. K. Adzamli, D.A. Yablonskiy, and M.R. Chicoine Albumin-binding MR blood pool agents as MRI contrast agents in an intracranial mouse glioma model Magn Reson Med 49 2003 586 590 (Pubitemid 36262830)